Introduction
Selective IgA deficiency (IgAD) and common variable immunodeficiency (CVID) represent the most prevalent primary immunodeficiency diseases in Caucasians, characterized by low or absent levels of serum IgA, or of all switched immunoglobulin isotypes, respectively. 1, 2 The diagnosis of CVID is also based on an inability to mount protective antibody responses in the presence of normal numbers of circulating B cells and exclusion of other causes of antibody deficiency. 2, 3 While many individuals with IgAD are asymptomatic, some suffer from an increased susceptibility to infections of the respiratory and gastrointestinal tract. CVID shows a highly variable clinical presentation and outcome. The clinical picture is dominated by upper and lower respiratory tract infections, leading to chronic lung disease, bronchiectasis, and eventually death. [2] [3] [4] Moreover, granulomatous inflammation, gastrointestinal disorders, autoimmunity and malignancies constitute complicating factors. 2, 3 The main treatment of primary antibody deficiencies is replacement immunoglobulin therapy administered by the intravenous (IVIG) or subcutaneous (SCIG) route. Restoration of physiological levels of IgG in the patient's blood has been a profound therapeutic advance, preventing, or alleviating, the severity of infections. [5] [6] [7] Several authors have demonstrated that B cells from IgA deficient subjects and CVID patients undergo class switch recombination (CSR) when stimulated through CD40 (TNFRSF5)
together with Interleukin-4 (IL-4) or Interleukin-10 (IL-10), leading to reconstitution of IgG and IgA production ex vivo. [8] [9] [10] [11] [12] However, these effects have not yet been established in vivo and it remains to be seen if targeting of the CD40 molecule and stimulation with IL-4 and IL-10 are tolerated and therapeutically effective in humans. 13, 14 Immunomodulatory intervention with low-doses of IL-2 has shown promise in vivo, despite insufficient evidence and proof of safety to support its routine use. [15] [16] [17] [18] For personal use only. on November 16, 2017 show that IL-21 can regulate immunoglobulin production both positively and negatively, depending on co-stimulation with IL-4 and anti-CD40 antibodies. 26 Finally, IL-21R/IL-4 double-deficient mice exhibit a CVID phenotype, with remaining IgM production, pointing out a critical role for IL-21 in regulating immunoglobulin switching.
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In the present study we evaluated an IL-21 based approach to induce immunoglobulin production in B cells from patients with common variable immunodeficiency or selective IgA deficiency ex vivo.
Patients and methods

Human subjects
Thirty-four patients with an established diagnosis of CVID, according to the ESID criteria, were included. 27 The patients received monthly intravenous or weekly subcutaneous gammaglobulin replacement therapy. Clinical characteristics and the flow cytometric analysis of B cell subpopulations of all included CVID patients are shown in Supplementary or Interleukin-21 was added in a final concentration of 10 ng/ml and Interleukin-2,
Interleukin-4, Interleukin-6, Interleukin-7 and Interleukin-15 at 0.5 ng/ml (all from ImmunoTools, Friesoythe, Germany). Anti-human CD40 monoclonal antibody (mAb, clone S2C6) or anti-human CD3 mAb (clone CD3-2) was added at 2 µg/ml (both from Mabtech AB, Stockholm, Sweden). Tetanus and diphtheria toxoid was purchased from Statens Serum Institut (Copenhagen, Denmark).
Flow cytometry (FCM)
Single-cell suspensions were prepared from PBMC and immunophenotyping of lymphocytes was performed by four-color cytometry on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) using the CellQuest software (BD Biosciences) as described previously. 29 Three cocktails of monoclonal antibodies were used to determine B cell and plasma cell populations: (1), anti-CD19-PC7, anti-CD27-FITC (both from DAKO, Glostrup, Denmark), 
RNA isolation and real-time quantitative RT-PCR
RNA was extracted from 1x10 6 
Sequence analysis of the IL-21 gene
Sequence-specific primers were used to amplify all exons of the IL-21 gene as previously described by Salzer et al. 30 The PCR products were run in a 1% agarose gel and specific
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From bands were excised using a sterile scalpel. The PCR products from the agarose slices were purified using the QIAquick Gel Extraction Kit (Qiagen) and sent for direct sequencing (Macrogen, Seoul, Korea).
Results
IL-21 cooperates with IL-2 and IL-4 to potentiate immunoglobulin production in anti-
CD40-activated human B cells
To compare the efficacy of IL-21 with known inducers of immunoglobulin production, freshly isolated PBMC from healthy donors were stimulated with IL-4, IL-10 or IL-21 at 10 ng/ml alone or in combination with an anti-CD40 mAb at 2 µg/ml. IL-21 stimulation alone 
IL-21 induces immunoglobulin production in individuals with CVID or IgAD
To investigate whether IL-21 stimulation is effective in individuals with an established diagnosis of CVID (n=34) or IgAD (n=10), we studied Ig secretion in patient's PBMC using an ELISPOT single cell assay. Cells were cultivated with either IL-21 (10 ng/ml) alone or together with IL-4 (0.5 ng/ml) or with addition of anti-CD40 mAb (2 µg/ml). A B cell differentiation protocol consisting of 10 ng/ml of IL-10 plus 2 µg/ml of anti-CD40 mAb was used for comparison, as described by Hummelshoj et al. Figure 1A) . In CVID patients, toxoidspecific IgG was absent in samples stimulated by IL-21, IL-4 and anti-CD40 mAb alone.
However, when diphtheria or tetanus toxoid was added during cell culture, a small amount of specific-antibodies was detected (Supplementary Figure 1A) .
Involvement of active CSR in IL-21-reconstituted immunoglobulin production in individuals with CVID or IgAD
To elucidate the molecular mechanism involved in immunoglobulin production induced by IL-21 plus IL-4 and mAb anti-CD40 stimulation, mRNA levels were analyzed for activation- 
Expression of IL-21 and IL-21R and sequencing of the IL-21 gene in individuals with
CVID
Given that T cell abnormalities are common in CVID, we also studied the expression of IL-21
and IL-21R mRNA upon activation of T cells stimulated by an anti-human CD3 mAb. Thirty patients with CVID were compared to twenty-two healthy individuals, randomly selected from a pool of blood donors. In CVID patients, expression of IL-21 and IL-21R mRNA following 14h of stimulation was ~10 to 16% lower compared to the mean values of healthy controls (Supplementary Figure 1C) . The same trend was seen in unstimulated samples.
We subsequently screened sixteen unrelated individuals with an established diagnosis of CVID for mutations in the IL-21 gene. These patients were all included in the experiments evaluating involvement of CSR induced by IL-21 ( Figure 4A-B) . We found no mutations in Ig-secreting cells in addition to its effects on CSR. [41] [42] [43] We confirm that the number of CD138 + circulating peripheral blood plasma cells is reduced in patients with CVID and might thus contribute to the lack of switched immunoglobulin isotypes. While CD138 + plasma cells generated within 7 days of culture with IL-21 only marginally contributed to the overall immunoglobulin production, it is subject to future studies if prolonged administration of IL-21 in vivo might further promote the differentiation of circulating plasma cells into longlasting immunoglobulin producers.
Given that IL-21 is a crucial factor for the differentiation of normal mature human B cells into
Ig-secreting cells, we hypothesize that alterations in the IL-21 gene could be responsible for show impaired growth and differentiation capacity, associated with a skewing of cytokine production towards a pro-apoptotic pattern. 49 Moreover, increased apoptosis of CD20 + IgA + B cells has previously been proposed to be involved in the etiology of IgAD. 10, 31 Our analyses 
